WallStSmart

CoStar Group Inc (CSGP)vsRafael Holdings, Inc. (RFL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CoStar Group Inc generates 362757% more annual revenue ($3.56B vs $980,000). CSGP leads profitability with a 2.1% profit margin vs 0.0%. CSGP earns a higher WallStSmart Score of 63/100 (C+).

CSGP

Buy

63

out of 100

Grade: C+

Growth: 8.7Profit: 4.5Value: 7.3Quality: 8.0
Piotroski: 2/9Altman Z: 3.10

RFL

Avoid

20

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: 0.44
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSGPUndervalued (+89.4%)

Margin of Safety

+89.4%

Fair Value

$451.36

Current Price

$30.46

$420.90 discount

UndervaluedFair: $451.36Overvalued
RFLUndervalued (+45.5%)

Margin of Safety

+45.5%

Fair Value

$2.20

Current Price

$2.28

$0.08 discount

UndervaluedFair: $2.20Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSGP6 strengths · Avg: 9.2/10
PEG RatioValuation
0.1510/10

Growing faster than its price suggests

EPS GrowthGrowth
1261.0%10/10

Earnings expanding 1261.0% YoY

Altman Z-ScoreHealth
3.1010/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
18.4%8/10

18.4% revenue growth

RFL2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

CSGP4 concerns · Avg: 2.8/10
Return on EquityProfitability
0.9%3/10

ROE of 0.9% — below average capital efficiency

Profit MarginProfitability
2.1%3/10

2.1% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
178.6x2/10

Premium valuation, high expectations priced in

RFL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$133.12M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CSGP

The strongest argument for CSGP centers on PEG Ratio, EPS Growth, Altman Z-Score. Revenue growth of 18.4% demonstrates continued momentum. PEG of 0.15 suggests the stock is reasonably priced for its growth.

Bull Case : RFL

The strongest argument for RFL centers on Debt/Equity, Price/Book.

Bear Case : CSGP

The primary concerns for CSGP are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 178.6x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.

Bear Case : RFL

The primary concerns for RFL are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

CSGP profiles as a growth stock while RFL is a value play — different risk/reward profiles.

CSGP carries more volatility with a beta of 0.73 — expect wider price swings.

CSGP is growing revenue faster at 18.4% — sustainability is the question.

CSGP generates stronger free cash flow (12M), providing more financial flexibility.

Bottom Line

CSGP scores higher overall (63/100 vs 20/100) and 18.4% revenue growth. RFL offers better value entry with a 45.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CoStar Group Inc

REAL ESTATE · REAL ESTATE SERVICES · USA

CoStar Group, Inc. provides online market information, analysis and services to the commercial real estate, hospitality, residential and related professional industries in the United States, Canada, Europe, Asia Pacific and Latin America. The company is headquartered in Washington, the District of Columbia.

Rafael Holdings, Inc.

REAL ESTATE · REAL ESTATE SERVICES · USA

Rafael Holdings, Inc. owns commercial real estate assets and interests in preclinical and clinical stage pharmaceutical companies. The company is headquartered in Newark, New Jersey.

Want to dig deeper into these stocks?